This article is more than 5 years old. Information may no longer be current.
ASH appoints 3 to executive committee
Click Here to Manage Email Alerts
The American Society of Hematology recently elected three new members to its executive committee, which serves as the organization’s governing body.
Charles S. Abrams, MD, will serve a 1-year term as vice president, followed by successive terms as president-elect and president.
Michelle Le Beau, PhD, and Martin Tallman, MD, both will serve 4-year terms as councillor.
Charles S. Abrams
Abrams, who served as ASH secretary from 2009 to 2012, is director of the University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia Blood Center for Patient Care & Discovery. He also is associate chief of hematology/oncology at the University of Pennsylvania.
Abrams’ research interests include phosphoinositide signaling in hematopoietic cells, platelet adhesion and thrombosis, and murine models of hemostasis.
Michelle Le Beau
Martin Tallman
Le Beau serves as director of University of Chicago Comprehensive Cancer Center and the University of Chicago Cancer Cytogenetics Laboratory. She also is the Arthur and Marian Edelstein professor of hematology/oncology at the University of Chicago.
Her research interests include cancer cytogenetics and genetics, acute myelogenous leukemia, therapy-related neoplasms and genetic pathways that lead to myelodysplastic syndrome.
Tallman is chief of the Leukemia Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Weill Cornell Medical College in New York. He also served as chair of ECOG’s leukemia committee for 16 years.
Tallman’s interests include clinical investigation in acute myelogenous and acute lymphoblastic leukemia, acute promyelocytic leukemia and hairy cell leukemia.
“This is an exciting yet challenging time for the field,” current ASH President Janis L. Abkowitz, MD, the Clement A. Finch professor of medicine and head of the division of hematology at the University of Washington School of Medicine, said in a press release. “While we are poised to make great discoveries, we are also faced with the continual threat of decreased federal research funding and significant changes in the health-care system that allows us to deliver care to our patients. Navigating these opportunities and challenges requires strong, visionary leaders like Drs. Abrams, Le Beau and Tallman.”